NCT04332692 Acute Heart Failure - COngestion Discharge Evaluation
| NCT ID | NCT04332692 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Hospital, Nancy, France |
| Condition | Acute Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 110 participants |
| Start Date | 2020-07-15 |
| Primary Completion | 2026-08-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 110 participants in total. It began in 2020-07-15 with a primary completion date of 2026-08-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute heart failure (AHF) is a major public health problem, associated with a 40% risk of death or re-hospitalisation at 3 months. This risk is significantly increased by insufficient decongestion at the end of hospitalisation for AHF assessed by a standardised clinical score, a natriuretic peptide dosage or by cardiac and pulmonary ultrasound . Adapting treatment according to lung congestion assessed by implantable devices (not reimbursed in France) improves the prognosis. However, due to the lack of a standardised congestion assessment, therapeutic adaptation in acute heart failure is currently empirical. The best multimodality approach to congestion evaluation is uncertain.
Eligibility Criteria
Inclusion Criteria: * Patients hospitalised for acute heart failure. * Patients considered clinically discharging from hospitalisation for acute heart failure. * Age ≥18 years * Patients having received complete information regarding the study design and having signed their informed consent form. * Patient affiliated to or beneficiary of a social security scheme. Exclusion Criteria: * Comorbidity for which the life expectancy is ≤ 3 months * Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular filtration rate \<15 ml/min/m2 at inclusion. * History of lobectomy or pneumonectomy lung surgery * Severe pulmonary or pleural pathology preventing reliable acquisition of lung ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc. * Pregnant woman, parturient or nursing mother * Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) * Adult person who is unable to give consent * Person deprived of liberty by a judicial or administrative decision, * Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the Public Health Code.
Contact & Investigator
Nicolas GIRERD, MD,PhD
PRINCIPAL INVESTIGATOR
CHRU of Nancy
Frequently Asked Questions
Who can join the NCT04332692 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04332692 currently recruiting?
Yes, NCT04332692 is actively recruiting participants. Contact the research team at n.girerd@chru-nancy.fr for enrollment information.
Where is the NCT04332692 trial being conducted?
This trial is being conducted at Vandœuvre-lès-Nancy, France.
Who is sponsoring the NCT04332692 clinical trial?
NCT04332692 is sponsored by Central Hospital, Nancy, France. The principal investigator is Nicolas GIRERD, MD,PhD at CHRU of Nancy. The trial plans to enroll 110 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.